Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Advances in Radiation Oncology|October 30, 2018
Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapyZhi Cheng, Lauren M Rosati, Linda Chen, et al.
Gynecologic Oncology|January 23, 2017
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancersKim A Reiss, Joseph M Herman, Deborah Armstrong, et al.
International Journal of Surgical Oncology|July 26, 2012
Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal CancerJessica A Smith, Aaron T Wild, Aatur Singhi, et al.
International Journal of Radiation Oncology, Biology, Physics|April 23, 2014
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapyAvani S Dholakia, Muhammad Chaudhry, Jeffrey P Leal, et al.
Annals of Surgical Oncology|February 7, 2022
Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative ToxicityColin S Hill, Lauren M Rosati, Chen Hu, et al.
Annals of Surgical Oncology|October 25, 2017
Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and EffectiveJohn F Ryan, Vincent P Groot, Lauren M Rosati, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2024
Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal AdenocarcinomaColin S Hill, Rose Parkinson, Elizabeth M Jaffee, et al.
Journal of Gastrointestinal Oncology|April 2, 2015
Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreasAaron T Wild, Avani S Dholakia, Katherine Y Fan, et al.
Practical Radiation Oncology|August 25, 2016
Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancerAvani D Rao, Elizabeth A Sugar, Daniel T Chang, et al.
Annals of Surgical Oncology|January 8, 2015
The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution ExperienceShalini Moningi, Avani S Dholakia, Siva P Raman, et al.
Pageof 5